Oncolytics Schedules FDA Meeting on April 16
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 06 2026
0mins
Should l Buy ONCY?
Oncolytics announced it has scheduled a Type C meeting with the FDA on April 16, to discuss a potential registrational development path for pelareorep in anal cancer. "We believe this upcoming FDA meeting is a critical step in advancing pelareorep toward a potential registration pathway in anal cancer. Our goal is to align with the FDA on the statistical analysis plan and sample size for a potential pivotal single-arm study in second-line and later SCAC," said Jared Kelly, CEO of Oncolytics Biotech. The meeting will focus on the potential to initiate a single-arm pivotal study evaluating pelareorep in combination with a checkpoint inhibitor in patients being treated with second-line and later therapy for squamous cell anal carcinoma. The company intends to discuss a study design enrolling approximately 60 to 70 patients with objective response rate as the primary endpoint to support a potential full approval.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ONCY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ONCY
Wall Street analysts forecast ONCY stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.120
Low
3.00
Averages
5.50
High
10.00
Current: 1.120
Low
3.00
Averages
5.50
High
10.00
About ONCY
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oncolytics Schedules FDA Meeting for Pelareorep Development
- FDA Meeting Scheduled: Oncolytics Biotech has scheduled a Type C meeting with the FDA on April 16, 2026, to discuss the registrational development path for its lead candidate Pelareorep in anal cancer, marking a significant advancement in the oncology immunotherapy sector.
- Clinical Study Design: The meeting will focus on designing a single-arm pivotal study enrolling approximately 60 to 70 patients, primarily evaluating the objective response rate of Pelareorep in combination with a checkpoint inhibitor for patients receiving second-line and later therapy for squamous cell anal carcinoma.
- Early Study Results: In Cohort 4 of the GOBLET study, the combination achieved an approximate 30% objective response rate with a median duration of response of 17 months in late-line patients, indicating its potential in treatment.
- Market Outlook: With approximately 54,000 cases of anal cancer globally each year, the anal cancer market is expected to double from $1.15 billion in 2025 to $2.3 billion by 2035, highlighting the significant commercial value of Oncolytics' development in this area.
See More
Oncolytics Schedules FDA Meeting to Discuss Anal Cancer Development Path
- FDA Meeting Scheduled: Oncolytics Biotech has scheduled a Type C meeting with the FDA on April 16, 2026, to discuss the registration development path for its immunotherapy pelareorep in anal cancer, marking a significant advancement in the company's efforts in this area.
- Clinical Trial Design: The meeting will focus on evaluating a single-arm pivotal study of pelareorep in combination with a checkpoint inhibitor, with plans to enroll approximately 60 to 70 patients and an objective response rate (ORR) as the primary endpoint to support potential full approval.
- Significant Clinical Efficacy: In Cohort 4 of the GOBLET study, the combination of pelareorep and checkpoint inhibitors achieved an ORR of approximately 30%, with a median duration of response of 17 months in late-line patients, significantly outperforming the real-world ORR of 10-14% and median duration of 9.5 months.
- Market Potential: With approximately 54,000 cases of anal cancer diagnosed globally each year, the anal cancer market is projected to double from $1.15 billion in 2025 to $2.3 billion by 2035, indicating substantial commercial opportunities in this sector.
See More
Biotech Investment Revives as Institutional Capital Flows Back
- Capital Flow Trend: In early 2026, institutional investors significantly increased financing activities in the biotech sector, indicating a strong interest in clinical-stage companies with validated science, which is expected to drive industry recovery and attract more investments.
- Precision Medicine Market Outlook: The global oncology precision medicine market is projected to reach $303 billion by 2035, growing at approximately 9% annually, providing substantial market opportunities for companies focused on precision medicine, particularly in cancer treatment.
- Oncolytics Biotech New Data: Oncolytics Biotech is set to present new mechanistic and translational data for its drug pelareorep at the upcoming AACR Annual Meeting, with preliminary results indicating that the drug may enhance tumor sensitivity to immunotherapy, potentially altering treatment strategies.
- OS Therapies Accelerated Approval Progress: OS Therapies' OST-HER2 immunotherapy has received an elevation to a Type B meeting with the FDA, signaling a transition to accelerated approval discussions following the submission of its clinical data package, which could provide a significant competitive advantage in the market.
See More
Global Oncology Market Set for Rapid Growth
- Market Size Forecast: The global oncology market is projected to reach $279.98 billion in 2026 and grow to $748.17 billion by 2035, indicating a structural shift from single-agent treatments to combination therapies and next-generation cell therapies.
- Immuno-Oncology Expansion: The immuno-oncology segment is expected to expand from $65.22 billion in 2025 to $170.19 billion by 2032, as approvals of combination therapies convert previously resistant tumors into viable treatment targets, driving market demand.
- Oncolytics Biotech New Data: Oncolytics Biotech will present new data at the 2026 American Association for Cancer Research Annual Meeting, indicating that its lead drug pelareorep can make tumors more susceptible to immunotherapy, particularly showing positive results in breast and gastrointestinal cancer trials.
- Clinical Trial Progress: Oncolytics' REO 033 trial demonstrated a total survival of 27 months in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer patients, with the FDA granting Fast Track Designation, which is expected to enhance the company's position in high-value markets.
See More
Global Oncology Market Expected to Reach $748.17 Billion
- Market Growth Potential: The global oncology market is valued at $279.98 billion in 2026 and is projected to reach $748.17 billion by 2035, indicating a strong trend towards a shift from single-agent treatments to combination platforms and next-generation cell therapies, potentially creating significant market opportunities for related companies.
- Immuno-Oncology Expansion: The immuno-oncology segment is expected to grow from $65.22 billion in 2025 to $170.19 billion by 2032, as the approval of combination therapies transforms previously resistant tumors into viable treatment targets, driving rapid industry growth.
- Oncolytics Biotech New Data: Oncolytics Biotech is set to present new mechanistic and translational data at the 2026 American Association for Cancer Research Annual Meeting, indicating that its lead drug pelareorep can enhance tumor sensitivity to immunotherapy, potentially providing crucial scientific support for the company in a competitive market.
- Clinical Trial Progress: Oncolytics' REO 033 trial for KRAS-mutant metastatic colorectal cancer shows an overall survival of 27 months and a 33% objective response rate, with the FDA granting Fast Track Designation, which is expected to create significant market opportunities for the company.
See More
Oncolytics Biotech Adjusts Clinical Trial Strategy
- Clinical Trial Adjustment: Oncolytics Biotech announced the termination of enrollment in its GOBLET study, shifting focus to registrational and registration-enabling studies, particularly for squamous cell anal cancer (SCAC) and metastatic colorectal cancer (CRC), aiming to optimize resource allocation and enhance R&D efficiency.
- FDA Meeting Plans: The company plans to meet with the FDA in mid-April to seek regulatory feedback on a single-arm registrational trial for SCAC, which it expects will be sufficient for U.S. approval of pelareorep, paving the way for future market access.
- Cost-Saving Measures: Oncolytics decided to end additional enrollments for the GOBLET Cohort 5 in Germany as part of its cost-saving measures, a decision that will help the company reallocate resources to more promising cancer treatment areas.
- Positive Market Reaction: Following the announcement of this strategic adjustment, Oncolytics Biotech (ONCY) saw its stock price rise, reflecting investor confidence in the company's new focus on SCAC and CRC, which may enhance its competitiveness in the biopharmaceutical market.
See More
Oncolytics Schedules FDA Meeting for Pelareorep Development
- FDA Meeting Scheduled: Oncolytics Biotech has scheduled a Type C meeting with the FDA on April 16, 2026, to discuss the registrational development path for its lead candidate Pelareorep in anal cancer, marking a significant advancement in the oncology immunotherapy sector.
- Clinical Study Design: The meeting will focus on designing a single-arm pivotal study enrolling approximately 60 to 70 patients, primarily evaluating the objective response rate of Pelareorep in combination with a checkpoint inhibitor for patients receiving second-line and later therapy for squamous cell anal carcinoma.
- Early Study Results: In Cohort 4 of the GOBLET study, the combination achieved an approximate 30% objective response rate with a median duration of response of 17 months in late-line patients, indicating its potential in treatment.
- Market Outlook: With approximately 54,000 cases of anal cancer globally each year, the anal cancer market is expected to double from $1.15 billion in 2025 to $2.3 billion by 2035, highlighting the significant commercial value of Oncolytics' development in this area.
See More
Oncolytics Schedules FDA Meeting to Discuss Anal Cancer Development Path
- FDA Meeting Scheduled: Oncolytics Biotech has scheduled a Type C meeting with the FDA on April 16, 2026, to discuss the registration development path for its immunotherapy pelareorep in anal cancer, marking a significant advancement in the company's efforts in this area.
- Clinical Trial Design: The meeting will focus on evaluating a single-arm pivotal study of pelareorep in combination with a checkpoint inhibitor, with plans to enroll approximately 60 to 70 patients and an objective response rate (ORR) as the primary endpoint to support potential full approval.
- Significant Clinical Efficacy: In Cohort 4 of the GOBLET study, the combination of pelareorep and checkpoint inhibitors achieved an ORR of approximately 30%, with a median duration of response of 17 months in late-line patients, significantly outperforming the real-world ORR of 10-14% and median duration of 9.5 months.
- Market Potential: With approximately 54,000 cases of anal cancer diagnosed globally each year, the anal cancer market is projected to double from $1.15 billion in 2025 to $2.3 billion by 2035, indicating substantial commercial opportunities in this sector.
See More
Biotech Investment Revives as Institutional Capital Flows Back
- Capital Flow Trend: In early 2026, institutional investors significantly increased financing activities in the biotech sector, indicating a strong interest in clinical-stage companies with validated science, which is expected to drive industry recovery and attract more investments.
- Precision Medicine Market Outlook: The global oncology precision medicine market is projected to reach $303 billion by 2035, growing at approximately 9% annually, providing substantial market opportunities for companies focused on precision medicine, particularly in cancer treatment.
- Oncolytics Biotech New Data: Oncolytics Biotech is set to present new mechanistic and translational data for its drug pelareorep at the upcoming AACR Annual Meeting, with preliminary results indicating that the drug may enhance tumor sensitivity to immunotherapy, potentially altering treatment strategies.
- OS Therapies Accelerated Approval Progress: OS Therapies' OST-HER2 immunotherapy has received an elevation to a Type B meeting with the FDA, signaling a transition to accelerated approval discussions following the submission of its clinical data package, which could provide a significant competitive advantage in the market.
See More
Global Oncology Market Set for Rapid Growth
- Market Size Forecast: The global oncology market is projected to reach $279.98 billion in 2026 and grow to $748.17 billion by 2035, indicating a structural shift from single-agent treatments to combination therapies and next-generation cell therapies.
- Immuno-Oncology Expansion: The immuno-oncology segment is expected to expand from $65.22 billion in 2025 to $170.19 billion by 2032, as approvals of combination therapies convert previously resistant tumors into viable treatment targets, driving market demand.
- Oncolytics Biotech New Data: Oncolytics Biotech will present new data at the 2026 American Association for Cancer Research Annual Meeting, indicating that its lead drug pelareorep can make tumors more susceptible to immunotherapy, particularly showing positive results in breast and gastrointestinal cancer trials.
- Clinical Trial Progress: Oncolytics' REO 033 trial demonstrated a total survival of 27 months in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer patients, with the FDA granting Fast Track Designation, which is expected to enhance the company's position in high-value markets.
See More
Global Oncology Market Expected to Reach $748.17 Billion
- Market Growth Potential: The global oncology market is valued at $279.98 billion in 2026 and is projected to reach $748.17 billion by 2035, indicating a strong trend towards a shift from single-agent treatments to combination platforms and next-generation cell therapies, potentially creating significant market opportunities for related companies.
- Immuno-Oncology Expansion: The immuno-oncology segment is expected to grow from $65.22 billion in 2025 to $170.19 billion by 2032, as the approval of combination therapies transforms previously resistant tumors into viable treatment targets, driving rapid industry growth.
- Oncolytics Biotech New Data: Oncolytics Biotech is set to present new mechanistic and translational data at the 2026 American Association for Cancer Research Annual Meeting, indicating that its lead drug pelareorep can enhance tumor sensitivity to immunotherapy, potentially providing crucial scientific support for the company in a competitive market.
- Clinical Trial Progress: Oncolytics' REO 033 trial for KRAS-mutant metastatic colorectal cancer shows an overall survival of 27 months and a 33% objective response rate, with the FDA granting Fast Track Designation, which is expected to create significant market opportunities for the company.
See More
Oncolytics Biotech Adjusts Clinical Trial Strategy
- Clinical Trial Adjustment: Oncolytics Biotech announced the termination of enrollment in its GOBLET study, shifting focus to registrational and registration-enabling studies, particularly for squamous cell anal cancer (SCAC) and metastatic colorectal cancer (CRC), aiming to optimize resource allocation and enhance R&D efficiency.
- FDA Meeting Plans: The company plans to meet with the FDA in mid-April to seek regulatory feedback on a single-arm registrational trial for SCAC, which it expects will be sufficient for U.S. approval of pelareorep, paving the way for future market access.
- Cost-Saving Measures: Oncolytics decided to end additional enrollments for the GOBLET Cohort 5 in Germany as part of its cost-saving measures, a decision that will help the company reallocate resources to more promising cancer treatment areas.
- Positive Market Reaction: Following the announcement of this strategic adjustment, Oncolytics Biotech (ONCY) saw its stock price rise, reflecting investor confidence in the company's new focus on SCAC and CRC, which may enhance its competitiveness in the biopharmaceutical market.
See More
